|Title:||EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer||Authors:||Kao, Hsiang-Fong
Yang, James Chih-Hsin
|Keywords:||afatinib;cetuximab;erlotinib;gefitinib;molecular targeted therapies;non-small-cell lung cancer;personalized medicine||Issue Date:||2013||Start page/Pages:||991-1003||Source:||Future Oncology||Abstract:||
Drugs that target the EGFR have a major impact on the treatment of advanced non-small-cell lung cancer (NSCLC). EGFR mutations in NSCLC are associated with a dramatic and sustained response to EGFR tyrosine kinase inhibitors (TKIs). This review summarizes the results of randomized trials using EGFR TKIs or EGFR monoclonal antibodies with chemotherapy in the first-line setting, and discusses several unresolved issues regarding the use of the EGFR TKIs as the first-line therapy in advanced NSCLC.
|Appears in Collections:||腫瘤醫學研究所|
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.